Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

CTOR

Citius Oncology Inc

Last Close
Dec 13 04:00PM ET
1.11
Dollar change
+0.04
Percentage change
3.74
%
Index- P/E4.53 EPS (ttm)0.24 Insider Own94.81% Shs Outstand2.34M Perf Week-22.92%
Market Cap82.11M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float0.35M Perf Month-9.02%
Income1.93M PEG- EPS next Q-0.06 Inst Own0.50% Short Float9.07% Perf Quarter-31.90%
Sales0.00M P/S- EPS this Y- Inst Trans1.09% Short Ratio0.02 Perf Half Y-90.07%
Book/sh-0.46 P/B- EPS next Y- ROA3.25% Short Interest0.03M Perf Year-89.38%
Cash/sh0.00 P/C- EPS next 5Y- ROE3.35% 52W Range0.85 - 49.00 Perf YTD-89.85%
Dividend Est.- P/FCF- EPS past 5Y- ROI4.19% 52W High-97.73% Beta-0.33
Dividend TTM- Quick Ratio0.01 Sales past 5Y0.00% Gross Margin- 52W Low30.59% ATR (14)0.24
Dividend Ex-Date- Current Ratio0.01 EPS Y/Y TTM- Oper. Margin- RSI (14)47.24 Volatility13.20% 20.18%
Employees- Debt/Eq0.04 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price3.00
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q-44.59% Payout0.00% Rel Volume0.03 Prev Close1.07
Sales Surprise- EPS Surprise0.00% Sales Q/Q- EarningsNov 27 Avg Volume1.88M Price1.11
SMA200.78% SMA50-2.01% SMA200-84.80% Trades Volume59,346 Change3.74%
Date Action Analyst Rating Change Price Target Change
Nov-27-24Initiated Maxim Group Buy $3
Citius Oncology, Inc. is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.